ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 418,72
-0,17%
Dow Jones
42 128,59
0,45%
DAX
20 160,29
-0,30%
Brent Oil
80,415
-0,25%
Bitcoin
92 143,52
-2,48%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. L'Europe
  5. EU

  6. Celyad Oncology SA (CYAD) Cours

Celyad Oncology SA

Celyad Oncology SA (CYAD)

EU
0,52
0,00
( 0,00% )
Mis à jour : 16:35:35
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
0,52
Prix Achat
0,518
Prix Vente
0,539
Volume échangé
30 391
0,518 Fourchette du Jour 0,57
0,212 Plage de 52 semaines 1,22
Cap du marché
21,543M
Clôture Veille
0,52
Ouverture
0,549
Dernière Transaction
88
@
0.52
Dernière heure de transaction
16:25:08
Volume financier
-
VWAP
-
Volume moyen (3 m)
98 001
Actions en circulation
41 429 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,55
Bénéfice par action (BPA)
-0,2
Chiffre d'affairess
102k
Bénéfice net
-8,45M

À propos de Celyad Oncology SA

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.celyad.com
Siège social
Mont-saint-guibert, Walloon Brabant, Bel
Fondé
-
Celyad Oncology SA est coté dans le secteur Pharmaceutical Preparations de la Euronext avec le ticker CYAD. Le dernier cours de clôture d'Celyad Oncology était de 0,52 €. Au cours de la dernière année, les actions de Celyad Oncology ont été négociées dans une fourchette de prix de 0,212 € à 1,22 €.

Celyad Oncology compte actuellement 41 429 000 actions en circulation. La capitalisation boursière d'Celyad Oncology est de 21,54 € million. Celyad Oncology a un ratio cours/bénéfice (ratio PE) de -2.55.

CYAD Dernières nouvelles

Plus de nouvelles

Celyad Oncology Présentera au Congrès Annuel SITC 2024

Regulatory News: Celyad Oncology (Euronext: CYAD) (la “Société”), annonce aujourd'hui la présentation de deux posters lors de la 39e réunion annuelle de la Society for Immunotherapy of Cancer...

07 Octobre 2024
Business Wire

Celyad Oncology announces intention to terminate SEC reporting obligations

MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with...

08 Février 2024
GlobeNewswire Inc.

Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...

16 Janvier 2024
GlobeNewswire Inc.

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces, in accordance with Article 14 of the...

20 Décembre 2023
GlobeNewswire Inc.

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK...

15 Décembre 2023
GlobeNewswire Inc.

Celyad announces management change

MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of...

04 Décembre 2023
GlobeNewswire Inc.

Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2023 (GLOBE NEWSWIRE) -- regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance...

01 Décembre 2023
GlobeNewswire Inc.

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the...

21 Novembre 2023
GlobeNewswire Inc.

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the...

14 Novembre 2023
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.162-23.75366568910.6820.6830.518459060.58806722DE
4-0.23-30.66666666670.750.820.518379080.66521914DE
120.2675105.9405940590.25251.220.2525980010.74143105DE
260.261100.7722007720.2591.220.212544710.65269767DE
520.1540.54054054050.371.220.212370900.57227462DE
156-3.105-85.65517241383.6253.6250.212389981.089164DE
260-9.98-95.047619047610.512.080.212417933.37890985DE

CYAD - Frequently Asked Questions (FAQ)

What is the current Celyad Oncology share price?
The current share price of Celyad Oncology is 0,52 €
How many Celyad Oncology shares are in issue?
Celyad Oncology has 41 429 000 shares in issue
What is the market cap of Celyad Oncology?
The market capitalisation of Celyad Oncology is EUR 21,54M
What is the 1 year trading range for Celyad Oncology share price?
Celyad Oncology has traded in the range of 0,212 € to 1,22 € during the past year
What is the PE ratio of Celyad Oncology?
The price to earnings ratio of Celyad Oncology is -2,55
What is the cash to sales ratio of Celyad Oncology?
The cash to sales ratio of Celyad Oncology is 208
What is the reporting currency for Celyad Oncology?
Celyad Oncology reports financial results in EUR
What is the latest annual turnover for Celyad Oncology?
The latest annual turnover of Celyad Oncology is EUR 102k
What is the latest annual profit for Celyad Oncology?
The latest annual profit of Celyad Oncology is EUR -8,45M
What is the registered address of Celyad Oncology?
The registered address for Celyad Oncology is AXIS BUSINESS PARK, RUE ANDRE DUMONT 9, MONT-SAINT-GUIBERT, WALLOON BRABANT, 1435
What is the Celyad Oncology website address?
The website address for Celyad Oncology is www.celyad.com
Which industry sector does Celyad Oncology operate in?
Celyad Oncology operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
HYPDSHipay Group DS
0,0024 €
(200,00%)
1,83k
BNBSTonner Drones
0,0015 €
(50,00%)
100
ALLPLLepermislibre SA
0,588 €
(47,00%)
21,62k
PROACProactis SA
0,066 €
(16,81%)
1 000
ALCABCabasse SA
0,84 €
(16,67%)
15,71k
ALALOAcheterLouerFR
0,09 €
(-18,18%)
111,09k
ALTHETheraclion
0,232 €
(-17,14%)
32,91k
MLPACPacte Novation
8,35 €
(-14,80%)
3
MLVIRVirtualware 2007 SA
7,40 €
(-11,90%)
150
NYRNyrstar NV
0,0732 €
(-11,81%)
50,69k
ATOAtos SE
0,0022 €
(10,00%)
1,73B
BCPBanco Comercial Portugues SA
0,4793 €
(-0,19%)
35,08M
ALVERVergnet
0,0017 €
(-5,56%)
18,84M
ALCYBCybergun
0,0001 €
(0,00%)
16,61M
INGAING Groep NV
15,504 €
(2,95%)
8,44M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

EU
CYAD
Celyad Oncology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés